Clinical trial · Interventional
Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer
A Phase 2 Study of LY573636-Sodium Administered as an Intravenous Infusion on Day 1 of a 21-Day Cycle as Third-line Treatment in Patients With Unresectable, Metastatic Non-Small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective is to estimate the time to progressive disease for patients who receive LY573636-sodium (hereafter referred to as LY573636) after two previous treatments for metastatic non-small cell lung cancer. Patients will receive an intravenous infusion of study drug once every 21 days. Computed tomography (CT)-scans will be done before the first dose and then after every other treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small-Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LY573636-sodium | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- LY573636
- interventionNames
- Drug: LY573636-sodium
Primary outcomes (1)
- measure
- Time to Progression
- timeFrame
- First dose to measured progressive disease or death from study disease up to 10.35 months
- description
- Defined as the time from date of first dose to the first observation of progression of disease (PD) or death from study disease. PD was determined using the Response Evaluation Criteria In Solid Tumors (RECIST) criteria (version 1.0). PD is ≥20% increase in sum of longest diameter of target lesions and/or a new lesion.
Secondary outcomes (7)
- measure
- Progression-Free Survival
- timeFrame
- First treatment dose to measured progressive disease or death from any cause up to 10.35 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of metastatic non-small-cell lung cancer * At least 18 years of age * Have received 2 previous treatment regimens for metastatic non-small-cell lung cancer Exclusion Criteria: * Serious pre-existing medical conditions * Previous cancer (except skin cancer, excluding melanoma) * Have received 3 or more previous treatment regimens for metastatic non- small-cell lung cancer * Active treatment with Coumadin
References
Publications (0)
Data not yet available